Project Grant R01HL187988
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $770K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,265,021 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates pathologic fibroblast subsets unique to silicosis, a chronic and potentially fatal fibrotic disease caused by inhalation of crystalline silica. Recent worldwide outbreaks among workers cutting engineered stone for countertops have underscored the need to...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco (UCSF) $297,806 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the senescence marker P16INK4A in alveolar epithelial stem cells during injury-triggered differentiation. The research examines how alveolar type 2 cells (AT2s), which serve as lung stem cells, differentiate into alveolar type 1 cells and how the...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $163,836 on July 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research into the cellular and molecular pathways that drive pulmonary silicosis. The research dissects bidirectional signaling networks between fibroblasts and macrophages in silica-induced granulomatous lung injury. Preliminary single-cell RNA sequencing identified...
- The National Heart Lung and Blood Institute awarded $827,439 to Lundquist Institute For Biomedical Innovation At Harbor-UCLA Medical Center on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms by which perinatal nicotine vaping exposure dysregulates pulmonary group 2 innate lymphoid cells (ILC2s) and promotes allergic asthma development in offspring. The research employs electronic nicotine delivery system (ENDS) exposure models and...
- The National Heart, Lung, and Blood Institute awarded $174,296 to The Regents of the University of California, San Francisco on December 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This Project Grant (F32HL184606) supports development of antibody-drug conjugates (ADCs) to specifically target small molecule kinase inhibitors and kinase-directed molecular glue degraders to pathogenic fibroblasts in pulmonary fibrosis. The recipient will use single-cell...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $766,557 for a Project Grant (R01HL188011) on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into bronchiolization—the takeover of alveoli by airway cell types—a hallmark of interstitial lung diseases including idiopathic pulmonary fibrosis. The project uses CRISPR/Cas9 genome editing to generate mouse models carrying patient mutations in...